Sanofi Canada, the manufacturer of Lantus, is proud to announce that Health Canada has approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) indicated as a once-daily long-acting basal insulin for reaching glycemic control in adults living with type 1 and type 2 diabetes mellitus.  Toujeo™is expected to be available in Canada at the beginning of Q3 2015.

"Nearly 50 percent of people treated with insulin injections for their diabetes are not achieving their glycemic goals," said Dr. Stewart Harris, Professor at the Schulich School of Medicine at Western University London, Ontario. "Ensuring appropriate intensification and adherence to treatment can be a challenge for both patients and healthcare professionals due to various factors such as hypoglycemia concerns.  Toujeo is a new basal insulin option that may help patients to better manage their diabetes and achieve their glycemic goal."

Optimal glycemic control is fundamental to the management of diabetes.  Therapy in most individuals with type 1 or type 2 diabetes should be targeted to achieve an A1C ≤7.0% to reduce the risk of microvascular and, if implemented early in the course of disease, macrovascular complications.

"We are excited to offer people living with diabetes and their Health Care Professionals a new treatment option to help them better manage their condition," claims Martin Arès, Vice-President, Diabetes and Cardiovascular Business Unit.  "Sanofi has over eighty-five years of history in the treatment of diabetes.  Toujeo is the result of our ongoing drive and innovation to improve insulin therapy.  It offers healthcare professionals and people living with diabetes a new solution to reach and maintain their health goals."

For more details, go to: http://sanoficanada.mediaroom.com/2015-06-01-Toujeo-New-Basal-Insulin-Option-for-Adults-Living-with-Diabetes-Approved-by-Health-Canada